Key facts
- This page summarizes Carolyn F. Bonner's Form 3 filing for Medicus Pharma Ltd. (MDCX).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 31 Dec 2024, 16:04.
Carolyn F. Bonner - 31 Dec 2024 Form 3 Insider Report for Medicus Pharma Ltd. (MDCX)
- Reporting relationship
- President
- Issuer ticker
- MDCX
- Reported as of
- 31 Dec 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 31 Dec 2024, 16:04:12 UTC
- Next SEC filing
- 24 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Quinlan, as Attorney-in-Fact, for Carolyn F. Bonner
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Carolyn F. Bonner filed Form 3 for Medicus Pharma Ltd. (MDCX) on 31 Dec 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDCX
holding
Common Shares, no par value ("Common Shares")
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18,905
- Date
- 31 Dec 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MDCX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 31 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 62,500
- Exercise price
- $0.8100
- Footnotes
- F1, F2
MDCX
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 31 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 10,000
- Exercise price
- $2.75
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The option has vested and is exercisable as of the date hereof.
Footnote F2
Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
Footnote F3
The option was granted on December 17, 2024. The option is scheduled to vest quarterly in four equal installments over one year.
Footnote F4
Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
SEC remarks
Exhibit List - Exhibit 24.1 - Power of Attorney